Deutsche Bank announced on Tuesday that it had initiated coverage of bioMérieux with a price target of 121 euros, praising the group's flattering track record in terms of profitable growth.
Deutsche expects average annual sales growth of 7% over the period 2023-2028 and 11% in Ebit, outperforming its market and competitors.
This dynamism, he explains, should be underpinned by the extension of the offering into new specialties, by an already solid product portfolio, and by the quality of the management team.
In view of these catalysts and its attractive positioning in niche segments, the intermediary believes that its valuation is attractive today, based on a PER 2025 of 22x.
Copyright (c) 2024 CercleFinance.com. All rights reserved. The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).